The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

and this hormone binds to glucagon receptors in the liver. This binding stimulates breakdown of glycogen and the release of glucose into the circulation. Although glucose is the main mediator of ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

However, there are not yet any approved therapies that follow Opko’s modality of simultaneously activating the GLP-1 and glucagon receptors ... 1 development for the liver condition, while ...

investigating the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA ... alongside type 2 diabetes (T2D), chronic ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose ... metabolic dysfunction-associated fatty liver disease (MAFLD), and ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose ... metabolic dysfunction-associated fatty liver disease (MAFLD), and ...